A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST)
Objectives: To develop a mutation-based radiomics signature to predict response to imatinib in Gastrointestinal Stromal Tumors (GISTs). Methods: Eighty-two patients with GIST were enrolled in this retrospective study, including 52 patients from one center that were used to develop the model, and 30...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-12-01
|
Series: | European Journal of Radiology Open |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S235204772300031X |